BIOMAT Database Logo BIOMAT Database Logo

Iron therapy for haemodialysis patients. 1970

A J Morris

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D008297 Male Males
D004342 Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally. Allergy, Drug,Hypersensitivity, Drug,Drug Allergy,Allergies, Drug,Drug Allergies,Drug Hypersensitivities,Hypersensitivities, Drug
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A J Morris
Iron therapy in patients on maintenance haemodialysis.
September 1970, Lancet (London, England),
A J Morris
Oral or parenteral iron therapy in haemodialysis patients?
January 1977, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
A J Morris
Iron deficiency during erythropoietin therapy in haemodialysis patients.
January 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
A J Morris
Iron therapy in maintenance haemodialysis.
June 1975, Clinical science and molecular medicine. Supplement,
A J Morris
Efficacy and safety of intravenous iron therapy for HCV-positive haemodialysis patients.
January 2005, Nephron. Clinical practice,
A J Morris
Nomogram for individualizing supplementary iron doses during erythropoietin therapy in haemodialysis patients.
April 2002, Journal of clinical pharmacy and therapeutics,
A J Morris
Efficacy of low-dose i.v. iron therapy in haemodialysis patients.
December 2009, Nephrology (Carlton, Vic.),
A J Morris
Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
March 2008, International journal of clinical practice,
A J Morris
[Oral and i.v. iron therapy in haemodialysis patients (author's transl)].
January 1976, L'Ateneo parmense. Acta bio-medica : organo della Societa di medicina e scienze naturali di Parma,
A J Morris
Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy.
November 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Copied contents to your clipboard!